IHL-42X
for treatment of obstructive sleep apnoea
Phase II proof of concept clinical trial results.

ASX Ticker: IHL   |   NASDAQ Ticker: IXHL
Disclosure and Disclaimer

Not an offer of Securities This document has been independently prepared by Incannex Healthcare Limited (Incannex) and is provided for informational purposes only. This document does not constitute an offer to sell, or a solicitation of an offer to buy, any securities in any jurisdiction (in particular, the United States), or a securities recommendation. This document is not a prospectus, product disclosure statement or other offering document under Australian law or any other law, and will not be lodged with the ASIC. Summary Information This document contains a summary of information about Incannex and its activities that is current as at the date of this document. The information in this document is intended to be forecasts, forward looking statements or statements about the future matters for the purposes of the Corporations Act or any other applicable law. The occurrence of the events in the future are subject to risk, uncertainties and other actions that may cause Incannex’s actual results, performance or achievements to differ from those referred to in this document. Accordingly Incannex and its affiliates and their directors, officers, employees, agents, associates and advisers do not give any assurance or guarantee that the occurrence of these events referred to in the document will actually occur as contemplated. Statements contained in this document, including but not limited to those regarding the revenue, earnings, dividends, returns, potential growth of Incannex, industry growth or other projections and results, performance or achievements to differ from those referred to in this document. There can be no assurance that actual outcomes will not differ materially from these statements. To the maximum extent permitted by law, Incannex and any of its affiliates and directors, officers, employees, agents, associates and advisers: • disclaim any obligations or undertaking to release any updates or revisions to the information to reflect any change in expectations or assumptions; • do not make any representation or warranty, express or implied, as to the accuracy, reliability or completeness of the information, statements, opinions, forecasts, reports or other matters, express or implied, contained in, arising out of or derived from, or for omissions from, this document including, without limitation, any financial information, any estimates or projections and any other financial information derived therefore. Statements in this document are made only as of the date of this document unless otherwise stated and the information in this document remains subject to change without notice. No responsibility or liability is assumed by Incannex or any of its affiliates for updating Net Financial Product Advice. This document does not constitute financial product advice or take into account your investment objectives, taxation situation, financial situation or needs. This document consists purely of factual information and does not involve or imply a recommendation of a statement of opinion in respect of whether to buy, sell or hold a financial product. An investment in Incannex is considered to be speculative in nature. Before making any investment decision in connection with any acquisition of securities, investors should consult their own legal, tax and/or financial advisers in relation to the information in, and action taken on the basis of, this document. Information in this Document is Confidential: This document and the information contained within it are strictly confidential and are intended for the exclusive benefit of the persons to whom it is given. It may not be reproduced, disseminated, quoted or referred to, in whole or in part, without the express consent of Incannex. By receiving this document, you agree to keep the information confidential, not to disclose any of the information contained in this document to any other person and not to copy, use, publish, record or reproduce the information in this document without the prior written consent of Incannex, which may be withheld in its absolute discretion. Acceptance By attending an investor presentation or briefing, or accepting, accessing or reviewing this document you acknowledge and agree to the “Disclaimer” as set any information in this document or to inform any recipient of any new or more accurate information or any errors or mis-descriptions of which Incannex or any of its affiliates or advisers may become aware. Forward Looking Statements Certain information in this document refers to the intentions of Incannex, but these are not intended to be forecasts, forward looking statements or statements about the future matters for the purposes of the Corporations Act or any other applicable law. The occurrence of the events in the future are subject to risk, uncertainties and other actions that may cause Incannex’s actual results, performance or achievements to differ from those referred to in this document. Accordingly Incannex and its affiliates and their directors, officers, employees and agents do not give any assurance or guarantee that the occurrence of these events referred to in the document will actually occur as contemplated. Statements contained in this document, including but not limited to those regarding the possible or assumed future costs, performance, dividends, returns, revenue, exchange rates, potential growth of Incannex, industry growth or other projections and any estimated company earnings are or may be forward looking statements. Forward-looking statements can generally be identified by the use of words such as “project”, “foreseen”, “plan”, “expect”, “aim”, “intend”, “anticipate”, “believe”, “estimate”, “may”, “should”, “will” or similar expressions. These statements relate to future events and expectations and as such involve known and unknown risks and significant uncertainties, many of which are outside the control of Incannex. Actual results, performance, actions and developments of Incannex may differ materially from those expressed or implied by the forward-looking statements in this document. Such forward-looking statements speak only as of the date of this document. There can be no assurance that actual outcomes will not differ materially from these statements. To the maximum extent permitted by law, Incannex and any of its affiliates and directors, officers, employees, agents, associates and advisers: • disclaim any obligations or undertaking to release any updates or revisions to the information to reflect any change in expectations or assumptions; • do not make any representation or warranty, express or implied, as to the accuracy, reliability or completeness of the information in this document, or likelihood of fulfillment of any forward-looking statement or any event or results expressed or implied in any forward-looking statement; and • disclaim all responsibility and liability for these forward-looking statements (including, without limitation, liability for negligence).
Company statement on clinical trial results

IHL42x has exceeded our expectations. It has shown substantial clinical benefit to people with obstructive sleep apnoea at the lowest dose given.

This not only means people can get the full benefit with a reduced risk of side effects, but also, during the low dose treatment period every subject was substantially below the legal driving limits for THC in their blood the morning after dosing, thus removing a significant hurdle for IHL-42X’s widespread use.
Obstructive sleep apnoea (‘OSA’)

OSA involves the narrowing of the upper airway during sleep, which interferes with a person’s breathing. Decreased oxygen uptake results in poor-quality sleep.

Untreated OSA leads to serious long-term adverse health outcomes including hypertension, cardiovascular disease, heart attack, cognitive impairments, anxiety and depression, irritability and daytime fatigue increasing the risk of accidents.

There are no pharmacotherapy (drug) treatments available to those afflicted. The current ‘standard of care’ is the Continuous Positive Airway Pressure (CPAP) machine, however, patient compliance to CPAP is low due to various factors related to patient discomfort.
## IHL-42X Obstructive Sleep Apnea

### Problem
OSA leads to serious long term adverse health outcomes but is also grossly undertreated. It is a highly prevalent condition and current treatment options (machines and devices) have poor patient compliance.

### Solution
IHL-42X has two pharmaceutical ingredients (THC and Acetazolamide) that target different aspects of OSA. Combined, these ingredients create a synergistic therapeutic effect, reducing the effects of OSA with low doses of each compound, minimising potential side effects and satisfying THC limits for impaired driving.

### Clinical development status

<table>
<thead>
<tr>
<th>Asset</th>
<th>Preclinical</th>
<th>Australian Phase 2 POC</th>
<th>FDA Pre-IND</th>
<th>FDA IND</th>
<th>FDA bioequivalence study</th>
<th>FDA Phase 2</th>
<th>FDA Phase 3</th>
<th>Anticipated Milestones</th>
</tr>
</thead>
<tbody>
<tr>
<td>IHL-42X Obstructive Sleep Apnea*</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Proposed open IND Q4 2022</td>
</tr>
</tbody>
</table>

For personal use only

---

Opportunity

IHL-42X Obstructive Sleep Apnea

No available pharmacotherapies

US $10B

Addressable market

6.2%

Annual Growth Rate

OVER 900M people globally have sleep apnoea

Unblinded and confidential interim clinical data provided to the patent examiner.

Patent claims considered novel and inventive.

Clinical development status

<table>
<thead>
<tr>
<th>Asset</th>
<th>Preclinical</th>
<th>Australian Phase 2 POC</th>
<th>FDA Pre-IND</th>
<th>FDA IND</th>
<th>FDA bioequivalence study</th>
<th>FDA Phase 2</th>
<th>FDA Phase 3</th>
<th>Anticipated Milestones</th>
</tr>
</thead>
<tbody>
<tr>
<td>IHL-42X Obstructive Sleep Apnea*</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Proposed open IND Q4 2022</td>
</tr>
</tbody>
</table>

For personal use only

---

Results Presentation

5
Milestones achieved

Completed proof of concept phase 2 clinical trial
- Results indicate that IHL-42X is effective at reducing AHI in patients with OSA and is well tolerated.
- IHL-42X also reduced oxygen desaturation index, and improved patient reported sleep quality and the number of awakenings during the night.
- The morning after dosing with low dose IHL-42X, THC levels in blood were below the prohibited limit for driving.

Feedback received from FDA at pre-IND meeting
- Incannex do not require animal studies to open IND
- Guidance was provided on the data that needs to be included in the IND application as well as design of pivotal clinical trials.

IHL-42X patent filed and international search report and opinion deemed key claims to be novel and inventive.
Opportunity

Key Observations from phase 2 clinical trial – patients treated and concept confirmed

01. IHL-42X in low dose form outperformed medium and high dose with respect to sleep, THC clearance and safety.

02. Low dose IHL-42X reduced average Apnoea Hypopnea Index (‘AHI’) by an average of 50.7% versus baseline; 25% of participants experienced greater than 80% reduction in AHI.

03. In low dose IHL-42X samples, THC concentrations in blood were below the limits for impaired driving the morning after dose administration on night 7.

04. No serious treatment emergent adverse events were reported during the clinical trial.

Apnoea hypopnea index (AHI) is the main measure for diagnosis and monitoring of disease, in patients with OSA. It is a serious sleep disorder in which breathing repeatedly stops and starts.
Strategic composition of dronabinol and acetazolamide makes IHL-42X an exciting novel potential treatment for OSA.

Low dose IHL-42X (2.5 mg dronabinol and 125 mg acetazolamide) reduced AHI to a greater extent than reported for its constituent pharmaceutical ingredients. Low Dose IHL-42X was observed to reduce AHI by an average of 50.7%, indicating synergistic effect and a novel patent opportunity.

Dronabinol
- Synthetic form of (-)-trans-Δ9-tetrahydrocannabinol (THC).
- Approved in US for treatment of HIV/AIDS induced anorexia and chemotherapy induced nausea and vomiting.
- Dampens afferent vagal feedback, stabilizes respiratory patterns and dilates upper airway.
- Two clinical trials to demonstrate effectiveness in reducing AHI in patients with OSA.
- AHI reduction with 2.5 mg dronabinol was 23.4%.

Acetazolamide
- Carbonic anhydrase inhibitor.
- Used to treat glaucoma, altitude sickness, epilepsy and other indications.
- Increases the difference between prevailing PCO2 and apnoeic PCO2.
- Demonstrated as an effective treatment for OSA in 14 clinical studies.
- AHI reduction was 23.9-27.6% relative to baseline with 250 mg dose.
Clinical Trial

**Incannex’s proof of concept clinical trial to assess the safety and efficacy of IHL-42X in patients with OSA.**

Compared three doses of IHL-42X to placebo at reducing AHI compared to baseline (primary endpoint).

**Other assessments included:**

- Oxygen desaturation index
- Plasma THC levels
- Patient reported sleep quality
- Sleep metrics captured by actigraphy
- Safety
**Study Design**

- **Baseline**
- **Placebo period**
- **IHL-42X period 1**
- **IHL-42X period 2**
- **IHL-42X period 3**

**Observation**
- Four period cross over study.
- Participants had OSA confirmed at baseline, once eligibility was confirmed they completed a single blind placebo treatment period followed by three double blind IHL-42X treatment periods.
- Each treatment period was seven days with an overnight sleep study on night seven to determine AHI and collect secondary endpoint data.
- Treatment periods were separated by seven-day washout periods.
- Adverse events were recorded and monitored for the duration of the study.
## Participant demographics

<table>
<thead>
<tr>
<th>Demographic</th>
<th>Results (Mean (Range))</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age</td>
<td>51.82 (39-64)</td>
</tr>
<tr>
<td>Sex (female)</td>
<td>3/11</td>
</tr>
<tr>
<td>Childbearing Potential (Yes)</td>
<td>1/11</td>
</tr>
<tr>
<td>Race</td>
<td>10 White, 1 Asian</td>
</tr>
<tr>
<td>Ethnicity</td>
<td>Not Hispanic or Latino</td>
</tr>
<tr>
<td>Height (cm)</td>
<td>178.16 (160-187.3)</td>
</tr>
<tr>
<td>Weight (kg)</td>
<td>92.23 (66.8-117)</td>
</tr>
<tr>
<td>BMI</td>
<td>28.93 (24.9-36.9)</td>
</tr>
<tr>
<td>Education (coded from 1-6)*</td>
<td>3.73 (1-6)</td>
</tr>
<tr>
<td>Marital Status</td>
<td>5 Married, 1 Never Married, 3 Divorced, 2 Domestic Partner</td>
</tr>
<tr>
<td>Handedness (Right)</td>
<td>10/11</td>
</tr>
<tr>
<td>English as Native Language (Yes)</td>
<td>10/11</td>
</tr>
<tr>
<td>AHI at baseline</td>
<td>42.8</td>
</tr>
</tbody>
</table>

*Education was coded with the following: 1 = 9th Grade; 2 = 12th Grade Diploma or GED; 3 = Some College, No Degree; 4 = Academic Associate Degree; 5 = Bachelor’s Degree; 6 = Master’s Degree
Results

IHL-42X reduced AHI at a group level.

- Low dose IHL-42X was the most effective dose strength with an average reduction in AHI of 50.7% compared to the baseline.
- When comparing the means of the treatment groups, the difference observed for both low and medium dose compared to baseline was statistically significant (p<0.05).
Results

IHL-42X reduced AHI when compared within participants.

- 25% of participants experienced greater than 80% reduction in AHI.
- All three doses of IHL-42X led to a statistically significant (p<0.001) reduction in AHI compared to placebo when calculated directly to each participant’s baseline.

- Low dose IHL-42X treatment led to a reduction relative to baseline in AHI of >50% in 62.5% of participants and >80% in 25% of participants.
Summary of AHI data

During IHL-42X treatment periods AHI was reduced compared to baseline and placebo treatment periods.

- This means that when treated with IHL-42X, the subjects’ breathing was interrupted less frequently during sleep.
- This supports Incannex’s hypothesis that IHL-42X is an effective treatment for OSA.

Low dose IHL-42X was more effective at reducing AHI than either the medium or the high dose.

- This is encouraging for Incannex’s development of IHL-42X as a lower dose will reduce the risk of side effects and the cost of goods.
Results

IHL-42X → reduced AHI to a greater extent than reported for acetazolomide and dronabinol as monotherapies.

- IHL-42X at a low and medium dose reduce AHI to a greater extent relative to baseline than acetazolamide (1) and dronabinol (2) at equivalent doses (based on extrapolation of published data with linear dose response curves with R² values of 0.93 and 1 for acetazolomide and dronabinol respectively).


For personal use only
Summary of comparison with dronabinol and acetazolamide

Low and medium dose IHL-42X reduced AHI to a greater extent than reported for dronabinol and acetazolamide monotherapies at equivalent doses.

- This supports Incannex’s hypothesis that dronabinol and acetazolamide are acting synergistically to treat OSA.
- This data provides Incannex with confidence that IHL-42X will meet the FDA’s combination rule where both APIs must contribute to the therapeutic effect of a fixed dose combination product.
- This supports Incannex’s hypothesis that IHL-42X is an effective treatment for OSA.
Results

**IHL-42X reduces oxygen desaturation index (ODI).**

- IHL-42X at a low and medium dose led to reduction in ODI of 59.7 and 59.0% respectively. These reductions were statistically significant (p<0.05).
Summary of ODI data

Low and medium dose IHL-42X significantly reduced oxygen desaturation index during sleep.

- This means that during low and medium dose IHL-42X treatment, subjects had more oxygen in their blood
- Low oxygen saturation, or high oxygen desaturation, can lead to:
  - oxidative stress which can damage cells and tissues
  - bursts of the stress hormone cortisol
  - insulin resistance and increased risk of diabetes
  - altered metabolism
  - Increased risk of cardiovascular disease
Results

THC clearance

- THC levels in blood samples collected the morning after dose 7 were below the limit of detection (0.1 ng/mL) in 37.5 % of low dose IHL-42X samples.
- The average THC concentration in blood samples from the morning after night 7 in the low dose IHL-42X treatment period was 0.20 ng/mL.
- The highest THC concentration detected in a sample from the low dose group was 0.45 ng/mL.

Country | THC blood concentration above which driving is prohibited
---|---
Canada | 2 ng/mL
Norway | 1.3 ng/mL
UK | 2 ng/mL
Ireland | 1 ng/mL
Germany | 1 ng/mL

Summary of THC clearance

Countries that have levels of THC in blood above which driving is prohibited have set limits at 1-2 ng/mL.

The morning after low dose IHL-42X 37.5% of subjects had no detectable THC in their blood.

In the low dose blood samples that did have detectable THC the average concentration was 0.20 ng/mL and the maximum was 0.45 ng/mL, both of which are below the permissible limits.

The THC clearance data indicates that low dose IHL-42X is unlikely to pose a risk for patients to legally drive while using the drug to treat their sleep apnoea.
Results

**IHL-42X → improved patient reported sleep quality.**

- Participants recorded their sleep quality or satisfaction every night through out the study as very poor, poor, fair, good or very good.

- During IHL-42X treatment periods, the percentage of participants that ranked their sleep as good or very good was increased, compared to placebo. This is an average across the seven nights of each treatment period, for all the participants.


Results

IHL-42X improved sleep metrics captured by actigraphy (wearable sleep monitor).

During IHL-42X treatment periods, subjects were asleep for a greater proportion of their time in bed (sleep efficiency)
(1) woke up fewer times
(2) and were awake for less time (wake after sleep onset (WASO))
(3) than during the placebo treatment period.
Summary of sleep quality

During IHL-42X treatment periods subjects reported a higher level of sleep satisfaction than placebo periods.

Data from the Actiwatch indicated that subjects were sleeping through the night better than during the placebo period.

These data support that IHL-42X improved sleep quality, despite a lack of improvement in secondary endpoints that focused on sleepiness, mood and quality of life.
Results

IHL-42X was well tolerated.

- No serious treatment emergent adverse events (TEAE) were reported during the study.
- Low dose IHL-42X had the lowest proportion of participants reporting TEAEs and the fewest number of total TEAEs compared to other treatment groups.
- One participant on high dose IHL-42X had a TEAE that caused them to be withdrawn from the study. However, they tested positive for illicit substances other than cannabis.
- One participant on placebo had a severe TEAE that was not linked to the study drug.
Safety summary

IHL-42X was well tolerated across all three dose levels.
- No serious adverse events (side effects) were reported during the study.
- The only severe adverse event was reported during the placebo treatment period and was not linked to the study drug.

Adverse event rates during the low dose IHL-42X treatment period were lower than even placebo.

These results support Incannex’s hypothesis that combining dronabinol and acetazolamide into IHL-42X will reduce the potential for side effects.
Results

Conclusions

01. Data from phase 2 proof of concept clinical trial supports the potential of IHL-42X as an effective and well tolerated treatment for OSA, meeting the unmet needs of millions of people.

02. IHL-42X reduced AHI, improved sleep quality with respect to both patient reported outcome and actigraphy, and did not lead to any adverse events beyond those expected based on what was expected from dronabinol and acetazolamide.

03. Low dose IHL-42X was the most effective of the doses tested in this study.
   - It reduced AHI by over half (on average) in trial participants and 25% of participants saw an 80% reduction in AHI.
   - Low dose IHL-42X has the lowest number of reported adverse events, even lower than placebo.
   - Low observed THC blood concentration amongst participants below limits for impairment to drive.

04. Patent application for IHL-42X considered “novel and inventive” by international patent examiner.

05. Pre-IND meeting completed with FDA and the next major development milestone for IHL-42X will be the commencement of the IND opening clinical trial.
Acknowledgments

Dr Jen Walsh and the team at UWA Centre for Sleep Science for work as a clinical trial site.

Prof Terry O’Brien and the team at The Alfred for work as a clinical trial site.

Novotech for managing the trial and study data.

Agilex for analysis of samples for THC and metabolite levels.
Media Enquiries
For media related enquiries please contact:

Joel Latham
joel@incannex.com.au

Investor Enquiries
For investor related enquiries please contact:

Brad Dilkes
investors@incannex.com.au

Partnership Enquiries
For partnership related enquiries please contact:

admin@incannex.com.au